Page 1198 - Basic _ Clinical Pharmacology ( PDFDrive )

1184 Index

Acute heart failure, 223–224. See also Heart Adenylyl cyclase, 30, 139, 140f Adrenocorticosteroids, 703–715. See also
failure Adherence (compliance), 1150–1151 specific types
Acute kidney injury, 254, 275 Adjuvant chemotherapy, 950 classification of, 703
Acute lymphoblastic leukemia (ALL), 969 Administration corticosteroids, synthetic, 709–714.
Acute mountain sickness, 260–261 alternative routes of, first-pass effect in, See also Corticosteroids, synthetic
Acute myelogenous leukemia (AML), 969, 47t, 48 glucocorticoids, naturally occurring,
974, 977 rate of, 51 704–709. See also Glucocorti-
Acute myocardial infarction Ado-trastuzumab emtansine, 972, 993 coids, naturally occurring
from female hormonal contraceptives, Adrenal androgens, 715 structures and properties of, 703, 704f
735 Adrenal cortex, 303 Adrenocorticotropic hormone (ACTH),
thrombolytics for, 619, 619b Adrenal steroid inhibitors 668f, 668–669, 669t
Acute renal failure mineralocorticoid antagonists, 265, adrenocortical steroids versus, 713
loop diuretics for, 263 717 diagnostic uses of, 670t
from potassium-sparing diuretics, 267 preparations available, 718t Adrenomedullin (AM), 315
Acyclovir synthesis inhibitors and glucocorticoid Adverse drug event (ADE), 18
herpes simplex virus treated with, 865t, antagonists, 715–717 Adverse drug reaction (ADR), 18, 65
866, 866f Adrenergic fibers, 90f, 93 Adverse effects, 39
topical dermatologic, 1074 Adrenergic neuron-blocking agents Afatinib, 968
varicella zoster virus treated with, 865t, guanethidine, 181–182, 191t Affordable Care Act (ACA), 1155
866, 866f reserpine, 179t, 182, 191t African trypanosomiasis drugs
Adalimumab Adrenergic neurons antiprotozoal, 931–935, 932t–933t.
description of, 993 cotransmitters in, 97–98 See also Antiprotozoal drugs
inflammatory bowel disease treated with, description of, 95, 96f–97f benznidazole, 933t, 934
1110–1112, 1111t Adrenergic transmission, 95–97, eflornithine, 931t, 934
psoriasis treated with, 1079 96f–97f melarsoprol, 931t, 934
rheumatic disorders treated with, Adrenoceptor, 98, 99t, 138–142 pentamidine, 931, 931t, 933
652–654, 654f alpha, 138f, 139, 139t suramin, 931t, 934
Adapalene, 1077 beta, 139t, 139–140, 140f Afterload, 215f, 216
Adaptive immune system, 979f, 979–980, biased agonists at, 141, 142b Agatoxin, 370t
981f, 982f definition of, 98 Age
Addiction, 575. See also Drugs of abuse desensitization of, 141 in drug metabolism, 70
animal models of, 575 dopamine, 139t, 140 on physiologic function, 1059, 1059f
clinical pharmacology of, 587–588 polymorphisms of, 142 Age-related macular degeneration drugs
definition of, 575 regulation of, 141 with Alzheimer’s and hypertension,
dopamine hypothesis of, 579b selectivity and affinities of, 141, 141t 1058, 1067
dopamine transporter in, 576, 576f, 577t structure of, 138, 138f in elderly, 1065
as maladaptive learning, 577t, 578–580 Adrenoceptor agonist drugs, Aging
nicotine, 583–584 137–155, 154t. See also androgens and anabolic steroids for, 742
opioid, 566 Sympathomimetics molecular basis of, 1058
receptors in, 576 alpha-receptor antagonists, 156–162, pharmacology in, 1058–1067. See also
G io protein-coupled, 576, 577f 170t–171t. Geriatric pharmacology
ionotropic, 576, 577f, 577t beta-receptor antagonists, 162–170, Agitation, antipsychotics for, 519. See also
relapse in, 578 170t–171t. Antipsychotic agents
Addison’s disease, 709–710 thyroid, action of beta blockers 696 Agomelatine, 287b
Adefovir dipivoxil, 886 Adrenocortical antagonists, 715–717 Agonist, 5, 6f. See also specific types
Adenohypophysis, 667, 668f abiraterone, 716–717 biased, 141
Adenosine aminoglutethimide, 715, 716f at beta receptors, 142b
arrhythmia treated with, 239t, 240t, etomidate, 715 binding molecule inhibition by, 5
246–247, 251t ketoconazole, 715, 716f definition of, 3, 20
in central nervous system, 380 metyrapone, 716, 716f drugs as mediators of, 20
on kidney, 259 mifepristone (RU-486), 717 full, 5, 6f
vasodilator actions of, 206b mineralocorticoid antagonists, 717 inverse, 5–6, 7f
Adenosine deaminase (ADA) deficiency, mitotane, 716f, 717 partial, 5–6, 6f, 24–25, 25f
984 preparations available, 718t receptor binding of, concentration-effect
Adenosine diphosphate, 608 trilostane, 716 curves and, 21–22, 22f
Adenosine triphosphate (ATP) Adrenocortical insufficiency Agonist-antagonist property, mixed,
in central nervous system, 380 acute, 710 25, 25f
functions of, 92t chronic (Addison’s disease), 709–710 Agranulocytosis, 695